Literature DB >> 17622518

Activation of the mGlu7 receptor elicits antidepressant-like effects in mice.

Agnieszka Palucha1, Kinga Klak, Piotr Branski, Herman van der Putten, Peter J Flor, Andrzej Pilc.   

Abstract

RATIONALE: Broad evidence indicates that modulation of the glutamatergic system could be an efficient way to achieve antidepressant activity. Metabotropic glutamate receptor (mGlu receptor) ligands seem to be promising agents to treat several central nervous system disorders, including psychiatric ones.
OBJECTIVES: The aim of our study was to investigate potential antidepressant-like activity of the first, selective, and bio-available mGlu7 receptor agonist, AMN082 (N,N'-dibenzyhydryl-ethane-1,2-diamine dihydrochloride), in wild-type (WT) and mGlu7 receptor knock-out (KO) mice.
MATERIALS AND METHODS: The forced swim test (FST) and the tail suspension test (TST) in mice were used to assess antidepressant-like activity of AMN082.
RESULTS: We found that AMN082, administered IP, induced a dose-dependent decrease in the immobility time of WT animals in the FST and TST, suggesting antidepressant-like potency of an mGlu7 receptor agonist. Moreover, AMN082 did not change the behaviour of mGlu7 receptor KO mice compared to WT littermates in the TST, while imipramine, used as a reference control, significantly reduced their immobility, indicating an mGlu7 receptor-dependent mechanism of the antidepressant-like activity of AMN082. However, at high doses, AMN082 significantly decreased spontaneous locomotor activity of both mGlu7 receptor KO mice and WT control animals, suggesting off-target activity of AMN082 resulting in hypo-locomotion.
CONCLUSIONS: These results strongly suggest that activation of the mGlu7 receptor elicits antidepressant-like effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17622518     DOI: 10.1007/s00213-007-0856-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  38 in total

1.  Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7.

Authors:  John F Cryan; Peter H Kelly; Hans C Neijt; Gilles Sansig; Peter J Flor; Herman van Der Putten
Journal:  Eur J Neurosci       Date:  2003-06       Impact factor: 3.386

2.  MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.

Authors:  Shigeyuki Chaki; Ryoko Yoshikawa; Shiho Hirota; Toshiharu Shimazaki; Maoko Maeda; Naoya Kawashima; Takao Yoshimizu; Akito Yasuhara; Kazunari Sakagami; Shigeru Okuyama; Shigetada Nakanishi; Atsuro Nakazato
Journal:  Neuropharmacology       Date:  2004-03       Impact factor: 5.250

3.  Anxiolytic-like effects of group III mGlu receptor ligands in the hippocampus involve GABAA signaling.

Authors:  Katarzyna Stachowicz; Ewa Chojnacka-Wójcik; Kinga Kłak; Andrzej Pilc
Journal:  Pharmacol Rep       Date:  2006 Nov-Dec       Impact factor: 3.024

Review 4.  Are compounds acting at metabotropic glutamate receptors the answer to treating depression?

Authors:  Agnieszka Palucha
Journal:  Expert Opin Investig Drugs       Date:  2006-12       Impact factor: 6.206

5.  mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity.

Authors:  M Fendt; S Schmid; D R Thakker; L H Jacobson; R Yamamoto; K Mitsukawa; R Maier; F Natt; D Hüsken; P H Kelly; K H McAllister; D Hoyer; H van der Putten; J F Cryan; P J Flor
Journal:  Mol Psychiatry       Date:  2007-08-21       Impact factor: 15.992

6.  Immunohistochemical localization of metabotropic glutamate receptors, mGluR7a and mGluR7b, in the central nervous system of the adult rat and mouse: a light and electron microscopic study.

Authors:  A Kinoshita; R Shigemoto; H Ohishi; H van der Putten; N Mizuno
Journal:  J Comp Neurol       Date:  1998-04-13       Impact factor: 3.215

Review 7.  Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system.

Authors:  D D Schoepp
Journal:  J Pharmacol Exp Ther       Date:  2001-10       Impact factor: 4.030

8.  mGluR7 is a metaplastic switch controlling bidirectional plasticity of feedforward inhibition.

Authors:  Kenneth A Pelkey; Gabriela Lavezzari; Claudia Racca; Katherine W Roche; Chris J McBain
Journal:  Neuron       Date:  2005-04-07       Impact factor: 17.173

9.  Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats.

Authors:  A Pilc; A Kłodzińska; P Brański; G Nowak; A Pałucha; B Szewczyk; E Tatarczyńska; E Chojnacka-Wójcik; J M Wierońska
Journal:  Neuropharmacology       Date:  2002-08       Impact factor: 5.250

10.  Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice.

Authors:  Alena Lira; Mingming Zhou; Nathalie Castanon; Mark S Ansorge; Joshua A Gordon; Jasmine H Francis; Maria Bradley-Moore; Josko Lira; Mark D Underwood; Victoria Arango; Hank F Kung; Myron A Hofer; René Hen; Jay A Gingrich
Journal:  Biol Psychiatry       Date:  2003-11-15       Impact factor: 13.382

View more
  44 in total

1.  Functional monoclonal antibody acts as a biased agonist by inducing internalization of metabotropic glutamate receptor 7.

Authors:  C Ullmer; S Zoffmann; B Bohrmann; H Matile; L Lindemann; Pj Flor; P Malherbe
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

2.  Regulation of N-methyl-D-aspartic acid (NMDA) receptors by metabotropic glutamate receptor 7.

Authors:  Zhenglin Gu; Wenhua Liu; Jing Wei; Zhen Yan
Journal:  J Biol Chem       Date:  2012-01-27       Impact factor: 5.157

3.  Nonselective suppression of operant ethanol and sucrose self-administration by the mGluR7 positive allosteric modulator AMN082.

Authors:  Michael C Salling; Sara Faccidomo; Clyde W Hodge
Journal:  Pharmacol Biochem Behav       Date:  2008-06-14       Impact factor: 3.533

4.  Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behavior.

Authors:  Christine E Gee; Daniel Peterlik; Christoph Neuhäuser; Rochdi Bouhelal; Klemens Kaupmann; Grit Laue; Nicole Uschold-Schmidt; Dominik Feuerbach; Kaspar Zimmermann; Silvio Ofner; John F Cryan; Herman van der Putten; Markus Fendt; Ivo Vranesic; Ralf Glatthar; Peter J Flor
Journal:  J Biol Chem       Date:  2014-03-04       Impact factor: 5.157

Review 5.  Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications.

Authors:  Shen Yin; Colleen M Niswender
Journal:  Cell Signal       Date:  2014-05-02       Impact factor: 4.315

Review 6.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 7.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  The metabotropic glutamate receptor 7 (mGluR7) allosteric agonist AMN082 modulates nucleus accumbens GABA and glutamate, but not dopamine, in rats.

Authors:  Xia Li; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2007-11-19       Impact factor: 5.250

9.  Effects of metabotropic glutamate receptor ligands on male sexual behavior in rats.

Authors:  Xia Li; Amanda Higley; Rui Song; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2012-08-30       Impact factor: 5.250

10.  Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies.

Authors:  S I Shyn; J Shi; J B Kraft; J B Potash; J A Knowles; M M Weissman; H A Garriock; J S Yokoyama; P J McGrath; E J Peters; W A Scheftner; W Coryell; W B Lawson; D Jancic; P V Gejman; A R Sanders; P Holmans; S L Slager; D F Levinson; S P Hamilton
Journal:  Mol Psychiatry       Date:  2009-12-29       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.